BPC-157 vs TB-500: Key Differences for Research (2026)
18 Jun 2026BPC-157 and TB-500 are the two most-studied peptides in preclinical tissue-repair research, and they’re often confused — or combined — despite acting through different mechanisms. This guide compares their mechanisms, research applications, and molecular profiles, and explains why the literature frequently pairs them. All discussion is for laboratory research use only.
BPC-157 vs TB-500: What Researchers Need to Know
BPC-157 and TB-500 (Thymosin Beta-4) are among the most studied peptides in tissue repair and recovery research. While both are frequently discussed in the context of healing, they operate through distinct mechanisms and have different research profiles. This comparison breaks down the key differences for researchers evaluating these compounds.
Mechanism of Action
BPC-157 (Body Protection Compound-157)
BPC-157 is a pentadecapeptide (15 amino acids) derived from a protective protein found in gastric juice. Its primary mechanisms in published research include upregulation of growth factor expression (VEGF, EGF, FGF), modulation of the nitric oxide (NO) system, promotion of angiogenesis (new blood vessel formation), and cytoprotective effects on gastrointestinal tissue. BPC-157 has been studied in over 100 preclinical trials, primarily in rodent models, covering tendon, ligament, muscle, nerve, and gastrointestinal tissue repair. A fuller account is in our BPC-157 research guide.
TB-500 (Thymosin Beta-4 Fragment)
TB-500 is a synthetic peptide fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein. Its primary mechanisms include sequestration of G-actin to promote cell migration, downregulation of inflammatory cytokines, promotion of angiogenesis through distinct pathways from BPC-157, and upregulation of laminin-5 for dermal repair. TB-500 research has focused heavily on cardiac tissue repair, dermal wound healing, and corneal healing models. A fuller account is in our TB-500 research guide.
Research Applications Compared
| Research Area | BPC-157 Evidence | TB-500 Evidence |
|---|---|---|
| Tendon/Ligament Repair | Strong — multiple rodent studies | Moderate — fewer direct studies |
| Muscle Tissue | Strong — crush injury models | Moderate — cell migration focus |
| Gastrointestinal | Extensive — origin in gastric juice | Limited research |
| Cardiac Tissue | Limited — some vascular studies | Strong — cardiac repair models |
| Dermal/Wound Healing | Moderate — angiogenesis focus | Strong — laminin-5 upregulation |
| Neurological | Emerging — nerve repair studies | Emerging — neuroprotection |
| Inflammatory Response | Strong — NO system modulation | Strong — cytokine regulation |
Molecular Profile
| Property | BPC-157 | TB-500 |
|---|---|---|
| Amino Acids | 15 | 43 (fragment of TB4) |
| Molecular Weight | ~1419 Da | ~4963 Da |
| Origin | Gastric juice protein | Thymus gland protein |
| Stability | Highly stable in gastric acid | Moderate stability |
| Solubility | Water-soluble | Water-soluble |
| Storage (sealed vial) | Lyophilized: -20°C long-term | Lyophilized: -20°C long-term |
Why Researchers Combine BPC-157 and TB-500
Due to their complementary mechanisms — BPC-157 primarily working through growth factor upregulation and NO modulation, and TB-500 through actin sequestration and cell migration — some researchers investigate these compounds in combination. The theory is that BPC-157 promotes the vascular infrastructure for repair while TB-500 facilitates the cellular migration necessary to utilize that infrastructure.
ThePeptide.ca offers a BPC-157 + TB-500 Wolverine Blend (10mg) containing 5mg of each compound for researchers investigating synergistic effects. The mechanism case for the pairing is set out in our Wolverine Blend research overview.
Key Research Citations
- Seiwerth S, et al. "BPC 157's effect on healing." J Physiol Pharmacol. 2018. PMID: 30783776
- Tkalcevic VI, et al. "Enhancement of BPC-157 activity on collateral vessels." J Pharmacol Sci. 2007. PMID: 17704599
- Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing." Ann N Y Acad Sci. 2010. PMID: 20633111
- Philp D, et al. "Thymosin beta 4 promotes cardiac cell migration and survival." Ann N Y Acad Sci. 2006. PMID: 17182755
Where to Source Research-Grade BPC-157 and TB-500 in Canada
ThePeptide.ca is a Canadian-owned supplier shipping from British Columbia. BPC-157 is stocked as a single-compound 10 mg vial; TB-500 is not stocked on its own and is supplied only inside the Wolverine Blend. Every lot carries a batch-specific Certificate of Analysis published before the lot goes on sale, and we publish the measured figure for each lot rather than a catalogue-wide purity guarantee.
- BPC-157 10 mg — lot BPC10-0626-01, 99.64% by HPLC-UV at 214 nm, tested by Testides (Toronto).
- Wolverine Blend 10 mg (BPC-157 + TB-500) — lot HEAL-0626-01, 98.64% combined by the same method and laboratory. A blend is assayed as a single sample, so the figure is a combined one and sits lower than a single-compound vial by arithmetic rather than by quality.
Neither Testides nor Janoshik Analytical is accredited to ISO/IEC 17025. Accreditation is granted by an accreditation body for a named scope of methods and carries a certificate number that can be looked up; phrases such as "ISO 17025-aligned" are self-descriptions with no external assessment behind them. Ask us for an accreditation body and certificate number, ask every other supplier the same, and score the answers rather than the adjectives. Current lot certificates are published on our lab results page, and how to read a peptide COA walks through verifying one.
Shipping is free and tracked on every order, Canada-wide, with no minimum; orders are dispatched within 48 hours Monday to Friday from British Columbia. Volume pricing is automatic at checkout with no code — 10% off at 3 or more units, 15% at 5 or more, 20% at 10 or more, across all products with no exclusions.